Monoclonal antibody treatments for multiple sclerosis
Authors:
- John W. RoseJRJohn W. Rose
- John F. FoleyJFJohn F. Foley
- Noel G. CarlsonNCNoel G. Carlson
- 4 April 2009
- journal article
- research article
- Published by Springer Nature in Current Treatment Options in Neurology
- Vol. 11 (3) , 211-220
Abstract
Monoclonal antibodies (MAbs) may have great potential as therapies for autoimmune diseases. Their development as treatments for multiple sclerosis (MS) is promising. Partially effective immunomodulatory therapies have been helpful for many MS patients; however, for patients failing these immunomodulatory treatments, MAbs are an important new treatment option. Currently, MAbs are approved by the US Food and Drug Administration for treatment of many conditions, including autoimmune diseases. This article reviews four MAbs that have been investigated as potential treatments for MS. Of these MAbs, natalizumab is approved for treatment of MS. The other three MAbs (alemtuzumab, rituximab, and daclizumab) are all promising therapies in development for treatment of MS. Adverse effects are relatively mild for these MAbs; however, care in administration and management of these agents is emphasized. Overall, these MAb therapies have great promise in the treatment of MS.Keywords
This publication has 56 references indexed in Scilit:
- Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte functionNeurology, 2009
- Health‐related quality of life in multiple sclerosis: effects of natalizumabAnnals of Neurology, 2007
- The potential utility of B cell-directed biologic therapy in autoimmune diseasesRheumatology International, 2007
- The incidence and significance of anti-natalizumab antibodiesNeurology, 2007
- Direct inhibition of CD40L expression can contribute to the clinical efficacy of daclizumab independently of its effects on cell division and Th1/Th2 cytokine productionBlood, 2007
- Natalizumab reduces visual loss in patients with relapsing multiple sclerosisNeurology, 2007
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Regulatory CD56brightnatural killer cells mediate immunomodulatory effects of IL-2Rα-targeted therapy (daclizumab) in multiple sclerosisProceedings of the National Academy of Sciences, 2006
- Immunotherapy of experimental autoimmune encephalomyelitis (EAE): Differential effect of anti-IL-2 receptor antibody therapy on actively induced and T-line mediated EAE of the Lewis ratJournal of Autoimmunity, 1989
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986